

Materials and Methods

Study planning and ethical approval

The study was planned as part of a randomized-controlled bi-centric trial conducted by the outpatient center of the department of Internal and Integrative Medicine at Charité-Universitätsmedizin. The study was approved by the ethics committees of the Charité-Universitätsmedizin Berlin (approval number: EA4/141/13) and registered at ClinicalTrials.gov (registration number: NCT02099968).

Participants

Participants were recruited from the existing patients at study centers and through local newspaper announcements. Patients were first screened over the phone by a research assistant to assess eligibility. Eligible patients were invited for an assessment by a physician, where they were examined and provided detailed written information describing the study. If patients met all inclusion criteria and did not meet any exclusion criteria, informed consent was obtained and they were included in the study.

Male and female patients with metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria were included. Metabolic syndrome was defined as the presence of at least three out of five risk factors: i) increased waist circumference ($>94\text{cm}$ in men and $>80\text{cm}$ in women), ii) hypertriglyceridemia ($>150\text{mg/dl}$ (1.7mmol/l) or lipid-lowering medication), iii) low levels of high-density lipoprotein cholesterol (HDL-C; $<40\text{mg/dl}$ (1mmol/l) in men and $<50\text{mg/dl}$ (1.3mmol/l) in women or use of HDL-increasing medication (niacin or fibrate), iv) elevated blood pressure ($\geq 130/85\text{mm Hg}$ or use of antihypertensive medication), and v) elevated fasting plasma glucose ($\geq 110\text{mg/dl}$ or treatment for diabetes mellitus). Beyond NCEP ATP III criteria, patients were required to have been diagnosed with systolic hypertension (either being on anti-hypertensive medication or untreated). Further inclusion criteria included basic mobility and the ability to provide informed consent.

Exclusion criteria included i) diabetes mellitus type 1 or insulin bolus therapy (c-peptide $<1.2\text{ng/ml}$), ii) manifest treated coronary artery disease, myocardial infarction, pulmonary embolism, or stroke within the past 3 months, iii) heart failure \geq stage I NYHA, iv) peripheral

artery disease \geq stage 2, v) chronic kidney disease $>$ stage 2 (GFR $<$ 60ml/min), vi) manifest eating disorder, vii) dementia or manifest psychosis, or viii) other severe internal diseases.

Periodic fasting and plant-based Mediterranean diet intervention

Dietary interventions

The interventions in both groups were delivered as an intensive group-based behavioral intervention. The educational concept incorporated aspects of the mind–body program designed by the Benson–Henry Mind/Body Medical Institute of Harvard Medical School¹. The dietary education included counseling, comprehensive lectures and cooking classes.

Periodic fasting and modified DASH diet intervention

Intervention within the fasting arm (Fig. 1a) started with two calorie-restricted vegan days (max 1200kcal/day), followed by 5-days with a daily nutritional energy intake of 300-350 kcal/day, derived from vegetable juices and vegetable broth. After completion of fasting, weekly 6-hour multimodal sessions were provided for a total of 10 weeks; both groups received intensified nutritional counseling/nutritional classes and additional general lifestyle recommendations for exercise and stress reduction². The program entailed 10 hours of group sessions for the initial periodic fasting and 50 hours of nutritional education, which included lectures and cooking lessons. Similar to protocols from previous trials on periodic fasting in rheumatoid arthritis and diabetes mellitus type 2^{3, 4} patients were instructed to follow a modified DASH diet after the fasting period, with additional emphasis on plant-based and Mediterranean diet to optimize refeeding⁵⁻⁷.

Modified DASH diet intervention

The DASH group (Fig. 1a) was trained in the Dietary Approaches to Stop Hypertension (DASH) diet, a sodium-, fat- and sugar-reduced mainly plant-based diet, which has been shown to reduce high blood pressure^{8, 9}. The intervention was similarly delivered as an the fasting group-based behavioral intervention with aspects of the mind–body program of the Benson–Henry Mind/Body Medical Institute, Harvard Medical School¹. Overall, the program consisted of 50 hours of group sessions over a period of 10 weeks and also included comprehensive lectures and cooking lessons.

Randomization

Patients were randomly allocated to Fasting or DASH by block-randomization with randomly varying block lengths, stratified by a) study center, and b) the intake/non-intake of antihypertensive medication. The randomization list was created by a biometrician not involved in patient recruitment or assessment using the Random Allocation Software¹⁰. The list was password-secured and only the biometrician was able to access it. On this basis, sealed, sequentially numbered opaque envelopes containing the treatment assignments were prepared.

Outcome measures

Outcomes were assessed at baseline and at 1 and 12 weeks after randomization by a blinded outcome assessor who was not involved in patient recruitment, allocation, or treatment. Two primary outcome measures were defined: 24-hour ambulatory systolic blood pressure at week 12 and the Homeostasis Model Assessment (HOMA)-index at week 12.

Physician-assessed outcomes

Twenty-four-hour ambulatory blood pressure monitoring (ABPM) and pulse pressure recording were performed using a digital blood pressure monitor (Mobil-O-Graph® PWA, I.E.M., Stolberg, Germany)¹¹. Baseline ABPM measurements were performed within one week before the starting of the intervention, those at week 12 within a week after the end of the intervention. ABPM was initiated at the same time of day for each successive visit. The monitoring software automatically removed incorrect measurements using built-in algorithms. Blood pressure and heart rate values were further categorized as day or night values using each patient's reported awake and sleep times. Office blood pressure was measured in the hospital by a sphygmomanometer, using the average of three consecutive measurements after 5 min rest while sitting in a quiet room. Office blood pressure was measured at each time point, ambulatory blood pressure only at baseline and week 12.

Body weight, body fat percentage, and lean mass percentage were measured using the Omron BF 511 bioelectrical impedance device¹². BMI was calculated as the weight in kilograms divided by the square of height in meters. Waist circumference was measured by two research assistants using a measuring tape in the horizontal plane exactly midway between the iliac crest and the costal arch. Measures were repeated twice and the mean of both measures was used. If the two measures

differed by more than 1 cm, both measures were repeated. Hip circumference was measured in the horizontal plain at the maximal circumference of the hips or buttock region above the gluteal fold, whichever is larger, using the same approach as for waist circumference. Waist-hip-ratio was measured as the quotient of waist circumference and hip circumference¹³.

Laboratory measures

Blood samples were collected from the antecubital vein into vacutainer tubes and analyzed using the Modular P analyzer (Roche, Mannheim, Germany). Metabolic parameters included plasma and blood glucose levels, blood insulin levels, HbA1C, and HbA1C IFCC and were analyzed using standard procedures. HOMA index was calculated as blood insulin level ($\mu\text{U/ml}$) \times blood glucose level (mmol/l) / 22.5¹⁴. Further laboratory parameters included blood lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, LDL / HDL ratio, triglyceride), uric acid, blood creatinine level, estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), insulin-like growth factor 1 (IGF-1), and interleukin-6 (IL-6), triglyceride, fasting glucose level¹⁵. Samples were destroyed after the analysis and were not further stored.

Safety

All adverse events occurring during the study period were recorded. Patients experiencing adverse events were asked to see the study physician to assess their status and initiate any necessary response. The most common symptoms during the fasting period were mild weakness, headaches and mild perception of hunger. No serious adverse effects were reported. During the normocaloric diet periods no adverse effects were reported.

Multiple imputation

All analyses were conducted on an intention-to-treat basis, including all participants being randomized, regardless of whether or not they gave a full set of data or adhered to the study protocol. Missing data were multiply imputed by Markov chain Monte Carlo methods^{16, 17}.

Peripheral blood mononuclear cell analysis

PBMCs were processed and analyzed as described previously¹⁸. Whole blood staining was performed using antibodies against major leukocyte lineages. Quantitative measurement was performed using a high throughput sampler (BD) and a BD FACS CantoII (BD). Cell numbers per

μl blood were calculated as means from three independent measurements. Briefly, peripheral venous blood was obtained and mononuclear cells were isolated within 24 hours of collection by density gradient centrifugation using Biocoll and cryopreserved until further processing. Thawed cell aliquots were either labeled for extracellular antigens using fluorophore-conjugated monoclonal antibodies or CD4^+ cells were selected (Miltenyi CD4^+ Selection Kit). Cells (10^6) from CD4^+ and CD4^- fractions were placed onto U-bottom plates and re-stimulated for 4 hours at 37°C and 5% CO_2 in a humidified incubator in a final volume of $200\mu\text{l}$ RPMI 1640 (Sigma) supplemented with 10% FBS (Merck), 100U/ml penicillin (Sigma), 100mg/ml streptomycin (Sigma), 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma), 250ng/ml ionomycin (Sigma) and $1.3\mu\text{l/ml}$ Golgistop (BD). After re-stimulation, cells were labeled with Life/Dead Fixable Aqua Dead Cell Stain Kit, for 405nm excitation (Invitrogen), followed by labelling with surface antigen-specific fluorophore-conjugated monoclonal antibodies. Cells were then fixated and permeabilized by FoxP3/Transcription Factor Staining Kit (eBioscience), and subsequently labeled with intracellular-antigen-specific fluorophore-conjugated monoclonal antibodies. Antibodies are listed in Extended Data Table 9. Samples were analyzed using the FACSCanto II multicolor flow cytometer (BD). Data analysis was performed using FlowJo 10.3 (FlowJo LLC) and FCSExpress V6.02 (De Novo Software) software. Absolute cell numbers were calculated using the relative percentage of cell population compared to a marker used in the whole blood staining.

FlowSOM

Data was manually gated on single live cells and exported as FCS files in FCS Express V6.02 (De Novo Software). The automated analysis of FCS files was done by the FlowSOM¹⁹ algorithm, an R²⁰ bio-conductor package that uses self-organizing maps for dimensional reduction and visualization of flow cytometry data. All data was scaled and log-transformed on import. Cells were assigned to a Self-Organizing Map (SOM) with a 10×10 grid, grouping similar cells into 100 nodes. Each node in the FlowSOM tree gets a score indicating its correspondence with this requested cell profile. To visualize similar nodes in branches, a minimal spanning tree (MST) was constructed and cell counts were log scaled. To visualize the differences between the two time points, the mean percentage per sample group was computed in each cluster and then the statistical difference was performed by applying MWU test on every node within metaclusters. P values were

two-sided and analysis was performed using RStudio (version 3.4.4). The FlowSOM algorithm was run 3 times to ensure reproducibility of the results and $P < 0.05$ was considered to be statistically significant.

Medication data collection and cleanup

Antihypertensive drugs were normalized in order to track changes during intervention. In a first step, antihypertensives (according to the WHO ATC classification system), diuretics, beta blocking agents, calcium channel blockers and agents acting on the renin-angiotensin system as well as the given dosage were identified at V1 and at follow-up visit after three months (V3).

Secondly, drug dosage was normalized to the lowest drug dosage per patient and drug. The lowest drug dosage at baseline was set to one, while corresponding drug dosages at other time points were either zero if the medication was discontinued, one if there was no change in drug dosage between time points, smaller than one if the drug dosage was decreased or greater than one if the drug dosage was increased at a certain time point. The sum of the agents taken was calculated at each time point.

DNA isolation

For DNA based 16S rRNA gene and metagenomics sequencing, fecal samples were collected into RNALater containing tubes, shipped at room temperature and stored at -80°C until processing. The DNA isolation protocol has been previously described²¹. Briefly, samples were treated with 500 μl of extraction buffer (200mM Tris, 20mM EDTA, 200mM NaCl, pH 8.0), 200 μl of 20% SDS, 500 μl of phenol:chloroform:isoamyl alcohol (24:24:1) and 100 μl of zirconia/silica beads (0.1mm diameter). Samples were homogenized twice with a bead beater (BioSpec) for 2 min. After precipitation of DNA, crude DNA extracts were resuspended in TE Buffer with 100 $\mu\text{g}/\text{ml}$ RNase I and column purified to remove PCR inhibitors.

16S rRNA gene amplification and sequencing

Amplification of the V4 region (F515/R806) of the 16S rRNA gene was performed according to previously described protocols^{22, 23}. Briefly, for DNA-based amplicon sequencing 25ng of DNA was used per PCR reaction in a final volume 30 μl . The PCR conditions consisted of initial denaturation for 30s at 98°C , followed by 25 cycles (10s at 98°C , 20s at 55°C , and 20s at 72°C).

Each sample was amplified in triplicates and subsequently pooled. After normalization, PCR amplicons were sequenced on MiSeq PE300 platform (Illumina) at the Helmholtz Centre for Infection Research, Braunschweig, Germany.

Metagenomic DNA library construction and sequencing

60µl of total DNA was used for shearing by sonication (Covaris). Fragmentation was performed as follows; processing time: 150sec, fragment size: 200bp, intensity: 5, duty cycle: 10. Library preparation for Illumina sequencing was performed using the NEBNext Ultra DNA library prep Kit (New England Biolabs). The library preparation was performed according to the manufacturer's instructions. An input of 500ng of sheared DNA was used and the size selection was performed using AMPure XP beads with the following parameters. First bead selection: 55µl, and second: 25µl. Adaptor enrichment was performed using seven cycles of PCR using NEBNext Multiplex oligonucleotides for Illumina (Set1 and Set2, New England Biolabs). Sequencing was performed on NovaSeq PE1000 platform (Illumina) at the Helmholtz Centre for Infection Research, Braunschweig, Germany.

16S sequence processing

Reads retrieved from 16S amplicon sequencing were analyzed using the LotuS pipeline²⁴. The pipeline includes sequence quality filtering²⁵, read merging²⁶, adapter and primer removal, chimera removal²⁷, clustering²⁸ and taxonomic classification²⁹ based on the SILVA³⁰ database.

Shotgun metagenomic processing

Metagenomic shotgun sequences were processed within the NGLess framework³¹. Reads were quality filtered by a minimum read length of 45bp and a minimum Phred quality score of 25. Sequences passing that filter were mapped to the human genome (adapted from hg19; minimum 45bp match, 90% minimum identity) and filtered. Sequences identified as non-human were mapped with bwa³² to a) the IGC gene catalog³² with a minimum match size of 45bp and a minimum identity of 95%, b) 40 reference marker genes described in Ciccarelli et al.³³ and Sorek et al.³⁴ with a minimum match size of 45bp and a minimum identity of 97%. Reads mapping to the marker genes were extracted and further mapped to marker gene-based OTUs³⁵. Mapping statistics can be found in Extended Data Table 10.

Microbiome statistical analysis

Data pre-processing

Reads mapped to the IGC microbial gene catalog³³ were rarefied using the RTK³⁶ with default settings (95% of smallest total reads – here 15247497 reads/sample). Reads were mapped to the mOTUv2 taxonomic marker genes³⁵ were likewise rarefied (5838 reads/sample). Reads mapped to 16S OTUs (280 reads), to ensure sample compatibility regardless of sampling depth. For functional microbiome analysis, IGC genes were binned to KEGG KOs³⁷ based on the annotations in MOCAT2³⁷, then binned by averaging over KOs to KEGG modules and to Gut Microbial Modules (GMMs³⁸). 16S and mOTUv2 OTUs were binned at more rootwards taxonomic levels using the taxonomies provided with LotuS²⁴ and the mOTUv2 tool³⁵ respectively.

Alpha and beta diversity analysis

To assess alpha diversity, the RTK tool³⁶ was used, yielding Shannon diversity alongside other metrics as part of the rarefaction process. Beta diversity was assessed as community distances between samples computed using the vegan R package. For microbiome data, Bray-Curtis distances on rarefied samples was used, and for immunome data, Euclidean distances. Comparisons of distance profiles was performed using Mann-Whitney *U* tests.

Multivariate analysis

Multivariate analysis was carried out using Principal Coordinates Analysis (PcoA) as per the vegan R package, with same distance metrics as noted above. Where described, delta metrics for the first two dimensions of unconstrained ordination were computed. PERMANOVA tests for multivariate effect was done using the adonis function in the vegan³⁹ R package, stratified for patient ID.

Univariate contrast analysis

For all univariate analysis of clinical, immunome, or microbiome features, medication changes during the course of the study were accounted for as possible confounders using the following two-step procedure. The first step was a nested model comparison of a linear model for each feature, involving as predictors age, patient ID, sex and normalized dosage of each salient medication tracked at each time point, with the same model but additionally containing time point V1-V3 as a predictor. Models were compared using a likelihood ratio test as implemented in the lmer⁴⁰ R package, and adjusted for false discovery rate (FDR) using the Benjamini-Hochberg

(BH) procedure within each measurement space. In the second step, features with $FDR < 0.1$ were retained for a second phase of post-hoc tests using Mann-Whitney U comparisons between values at each pair of time points, BH FDR-adjusted between time point comparisons ($n = 3$) and requiring $FDR < 0.05$ to retain the result as significant. Standardized non-parametric effect sizes were taken using the (signed) Cliff's delta metric as implemented in the `orddom`⁴¹ R package.

Correlation analysis

To assess possible interactions between immune cells, taxa and quantitative phenotypes, another two-step test was used: first a Spearman correlation test using samples pooled across time points, and with Spearman's rho used as standardized signed effect estimate. P-values from this were FDR-adjusted with the BH method for each comparison of two data spaces, requiring $FDR < 0.05$ for significance. Second, a post-hoc test was done to account for dependency between same-donor samples: for each of two correlated features, a mixed effects model was fitted of the rank-transformed variable using the rank of the other as predictor, with patient ID as a random effect. This model was compared to a simpler model containing only the random effect under a likelihood ratio test as implemented in the `lmtree`⁴⁰ R package. The highest P-value for the two possible such models was taken, and $P < 0.05$ was additionally required to retain the correlation as robust. Correlation was visualized by the R packages `circilize`⁴² and `pheatmap`⁴³.

Re-analysis of previous datasets for comparison

Samples from Kushugulova et al.¹⁹ and Forslund et al.¹² were previously mapped to the IGC gene catalog and the mOTU marker genes; these abundances (binned at the level of KEGG and GMM modules as per the above in case of functional profiles). The samples were tested for significantly differential abundances between metabolic syndrome cases and controls (Kushugulova samples) or between metformin users and non-users (Forslund samples) using Mann-Whitney U tests with an additional nested model comparison post-hoc test to ensure signal (metabolic syndrome, metformin) is not reducible to the other, using a likelihood ratio test as implemented in the `lmtree`⁴⁰ package applied to rank-transformed data.

Machine-learning prediction of treatment response at the single-subject level

To estimate how well the omics data enables forecasting of the blood-pressure response in future patients, we performed a leave-one-patient-out cross-validation procedure. This approach represents the gold standard in the machine-learning community to carry out an acid-test that empirically evaluates the practical value of a predictive model⁴⁴. To this end, the set of n participants was iteratively split into $n - 1$ participants as training set, and the untouched data from the hold-out participant as the test set. All input variables were z-scored by centering to zero mean and unit-scaling to a variance of one⁴⁵. In each of n cross-validation folds, the logistic-regression algorithm was a natural choice of method for binary classification (no intercept term, L2 shrinkage penalty, hyper-parameter C defaulted to 1.0). Given that the number of variables was $> 10\times$ times larger than the number of participants, dimensionality reduction was necessary for a preliminary selection of a set of ten most promising input variables that could be relevant for outcome prediction. Forward-stepwise selection is an established means⁴⁶ to screen the relevance of several hundred quantitative measures. The first step identifies the single input variable among the p candidates, with the best p-value having a statistically significant association with the blood-pressure outcome. After adding this first variable to the empty null model, the second most significant (i.e., smallest p-value) was searched based on the remaining $p - 1$ input variables. Based on a two-variable model, the third most significant variable was searched based on $p - 2$ remaining variables, and so forth. This successive identification of the ten most promising among the p overall input dimensions did not bias the subsequently performed prediction performance estimate, because the entire variable reduction scheme was exclusively carried out on the $n - 1$ participants of the current cross-validation fold.. Based on the top 10 variables, the logistic-regression algorithm could be more robustly fit to these subselected ten input dimensions only. The ensuing predictive model was then explicitly validated by computing whether or not the obtained model parameters allowed for accurate derivation of the relevant blood-pressure response for the independent, unseen participant. In this way, the omics data of each patient in our dataset served as test observation once. Averaging these yes-no results over all n predicted, versus observed clinical responses, yielded an estimate of the expected forecasting accuracy of the predictive model in participants that we would observe in other or later acquired datasets.

For the sake of reproducibility and reuse, the Python code for this analysis can be found online (www.github.com/banilo/TO_BE_ADDED_LATER).

References

1. Benson H, Stuart M. *The wellness book. Mind–body medicine*. New York: Fireside; 1999.
2. Cramer H, Lauche R, Paul A, Dobos G. Mindfulness-based stress reduction for breast cancer—a systematic review and meta-analysis. *Current oncology*. 2012;19:e343-352
3. Li C, Sadraie B, Steckhan N, Kessler C, Stange R, Jeitler M, Michalsen A. Effects of a one-week fasting therapy in patients with type-2 diabetes mellitus and metabolic syndrome - a randomized controlled explorative study. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association*. 2017;125:618-624
4. Kjeldsen-Kragh J, Haugen M, Borchgrevink CF, Laerum E, Eek M, Mowinkel P, Hovi K, Forre O. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. *Lancet (London, England)*. 1991;338:899-902
5. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet*. 1994;343:1454-1459
6. De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, Delaye J. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. *Journal of the American College of Cardiology*. 1996;28:1103-1108
7. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. *Jama*. 2004;292:1440-1446
8. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR, Writing Group of the PCRG. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the premier clinical trial. *Jama*. 2003;289:2083-2093
9. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. Dash collaborative research group. *The New England journal of medicine*. 1997;336:1117-1124
10. Saghaei M. Random allocation software for parallel group randomized trials. *BMC medical research methodology*. 2004;4:26
11. Westhoff TH, Straub-Hohenbleicher H, Schmidt S, Tolle M, Zidek W, van der Giet M. Convenience of ambulatory blood pressure monitoring: Comparison of different devices. *Blood pressure monitoring*. 2005;10:239-242
12. Bosy-Westphal A, Later W, Hitze B, Sato T, Kossel E, Gluer CC, Heller M, Muller MJ. Accuracy of bioelectrical impedance consumer devices for measurement of body composition in comparison to whole body magnetic resonance imaging and dual x-ray absorptiometry. *Obesity facts*. 2008;1:319-324
13. World Health Organization. *Waist circumference and waist–hip ratio: Report of a who expert consultation*. Geneva: World Health Organization; 2011.
14. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding "insulin resistance": Both glucose resistance and insulin resistance are required to model human diabetes. *Metabolism: clinical and experimental*. 1991;40:908-917

15. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (procam) study. *Circulation*. 2002;105:310-315
16. Rubin DB. *Multiple imputation for nonresponse in surveys*. New York: Wiley; 1987.
17. Schafer JL. *Analysis of incomplete multivariate data*. London: Chapman & Hall; 1997.
18. Mahler A, Balogh A, Csizmadia I, Klug L, Kleinewietfeld M, Steiniger J, Susnjar U, Muller DN, Boschmann M, Paul F. Metabolic, mental and immunological effects of normoxic and hypoxic training in multiple sclerosis patients: A pilot study. *Frontiers in immunology*. 2018;9:2819
19. Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, Saeys Y. Flowsom: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry. Part A : the journal of the International Society for Analytical Cytology*. 2015;87:636-645
20. Team RC. R: A language and environment for statistical computing. 2014
21. Turnbaugh PJ, Hamady M, Yatsunencko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. *Nature*. 2009;457:480-484
22. Thiemann S, Smit N, Roy U, Lesker TR, Galvez EJC, Helmecke J, Basic M, Bleich A, Goodman AL, Kalinke U, Flavell RA, Erhardt M, Strowig T. Enhancement of ifngamma production by distinct commensals ameliorates salmonella-induced disease. *Cell host & microbe*. 2017;21:682-694 e685
23. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. Global patterns of 16s rRNA diversity at a depth of millions of sequences per sample. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108 Suppl 1:4516-4522
24. Hildebrand F, Tadeo R, Voigt AY, Bork P, Raes J. Lotus: An efficient and user-friendly otu processing pipeline. *Microbiome*. 2014;2:30
25. Lange A, Jost S, Heider D, Bock C, Budeus B, Schilling E, Strittmatter A, Boenigk J, Hoffmann D. Ampliconduo: A split-sample filtering protocol for high-throughput amplicon sequencing of microbial communities. *PloS one*. 2015;10:e0141590
26. Magoc T, Salzberg SL. Flash: Fast length adjustment of short reads to improve genome assemblies. *Bioinformatics*. 2011;27:2957-2963
27. Edgar RC. Uchime2: Improved chimera prediction for amplicon sequencing. *bioRxiv*. 2016:074252
28. Edgar RC. Uparse: Highly accurate otu sequences from microbial amplicon reads. *Nature methods*. 2013;10:996-998
29. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *Journal of molecular biology*. 1990;215:403-410
30. Yilmaz P, Parfrey LW, Yarza P, Gerken J, Pruesse E, Quast C, Schweer T, Peplies J, Ludwig W, Glockner FO. The silva and "all-species living tree project (ltp)" taxonomic frameworks. *Nucleic acids research*. 2014;42:D643-648
31. Coelho LP, Kultima JR, Costea PI, Fournier C, Pan Y, Czarnecki-Maulden G, Hayward MR, Forslund SK, Schmidt TSB, Descombes P, Jackson JR, Li Q, Bork P. Similarity of the dog and human gut microbiomes in gene content and response to diet. *Microbiome*. 2018;6:72

32. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, Arumugam M, Kultima JR, Prifti E, Nielsen T, Juncker AS, Manichanh C, Chen B, Zhang W, Levenez F, Wang J, Xu X, Xiao L, Liang S, Zhang D, Zhang Z, Chen W, Zhao H, Al-Aama JY, Edris S, Yang H, Wang J, Hansen T, Nielsen HB, Brunak S, Kristiansen K, Guarner F, Pedersen O, Dore J, Ehrlich SD, Meta HITC, Bork P, Wang J, Meta HITC. An integrated catalog of reference genes in the human gut microbiome. *Nature biotechnology*. 2014;32:834-841
33. Ciccarelli FD, Doerks T, von Mering C, Creevey CJ, Snel B, Bork P. Toward automatic reconstruction of a highly resolved tree of life. *Science*. 2006;311:1283-1287
34. Sorek R, Zhu Y, Creevey CJ, Francino MP, Bork P, Rubin EM. Genome-wide experimental determination of barriers to horizontal gene transfer. *Science*. 2007;318:1449-1452
35. Milanese A, Mende DR, Paoli L, Salazar G, Ruscheweyh HJ, Cuenca M, Hingamp P, Alves R, Costea PI, Coelho LP, Schmidt TSB, Almeida A, Mitchell AL, Finn RD, Huerta-Cepas J, Bork P, Zeller G, Sunagawa S. Microbial abundance, activity and population genomic profiling with motus2. *Nature communications*. 2019;10:1014
36. Saary P, Forslund K, Bork P, Hildebrand F. Rtk: Efficient rarefaction analysis of large datasets. *Bioinformatics*. 2017;33:2594-2595
37. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. Kegg: New perspectives on genomes, pathways, diseases and drugs. *Nucleic acids research*. 2017;45:D353-D361
38. Rajilic-Stojanovic M, Heilig HG, Molenaar D, Kajander K, Surakka A, Smidt H, de Vos WM. Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environmental microbiology*. 2009;11:1736-1751
39. Oksanen J, Blanchet F, Friendly M, Kindt R, Legendre P, McGlenn D, Minchin P, O'Hara R, Simpson G, Solymos P, Stevens M, Szoecs E, H. W. Vegan: Community ecology package. 2018
40. Zeileis A, Hothorn T. Diagnostic checking in regression relationships. *R News*. 2002;2:7-10
41. Rogmann JJ. Ordinal dominance statistics. 2013
42. Gu Z, Gu L, Eils R, Schlesner M, Brors B. Circlize implements and enhances circular visualization in r. *Bioinformatics*. 2014;30:2811-2812
43. Kolde R. Pheatmap: Pretty heatmaps. 2019
44. Hastie T, Tibshirani R, Friedman J. *The elements of statistical learning*. Heidelberg, Germany: Springer Series in Statistics; 2001.
45. Gelman A, Hill J. *Data analysis using regression and multi-level hierarchical models*. Cambridge University Press New York, NY, USA; 2007.
46. Harrell FE. *Regression modeling strategies, with applications to linear models, survival analysis and logistic regression*. New York: Springer; 2001.